Eli Lilly's CEO, Dave Ricks, announced that the company has already manufactured billions of doses of its next-generation oral weight-loss pill, orforglipron, in anticipation of a potential launch next year. This proactive manufacturing strategy is designed to meet the significant global demand expected for the new treatment, positioning it as a 'GLP-1 for all'. The company is preparing for global regulatory submissions for the once-daily pill by the end of the year. This move underscores Lilly's strategy to solidify its leadership in the rapidly expanding obesity drug market, where it faces competition from rivals like Novo Nordisk and Viking Therapeutics. Lilly is investing heavily in R&D, with plans to launch multiple new medicines over the next several years to avoid reliance on a single blockbuster therapy.